Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of Transgene's virus-based immunotherapies TG6002 and TG1050 in Greater China
? Transgene to receive $48 million paid in newly created Tasly Biopharmaceuticals shares
? Deals give Tasly Biopharmaceuticals full control over Greater China development and commercial rights to the oncolytic virus T601 and the therapeutic vaccine T101
? Development of these immunotherapies for the Chinese market will benefit from the significant resources and capabilities of Tasly Biopharmaceuticals
The press release is available on www.trangene.fr
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer